Hit #151 (Dendrite)

Dendrite (DRTE), a sales/marketing services provider to the pharmaceutical industry, is being acquired by French company Cegedim SA. The $751 million cash offer translates into a per-share price of $16, a discount of 9.8% to my average cost of $16.42.

I was hoping this to be a long-term winner but the stock hasn't budged since I bought it a couple of years ago.

Another company to watch here would be PDI (PDII), which still looks attractively valued.

---

Previous hit - Hyperion (#150)